Pharmacological treatment for COPD; GOLD 2017 changes direction.
作者信息
Singh Dave
机构信息
University of Manchester, Medicines Evaluation Unit, The Langley Building, University Hospital of South Manchester, Southmoor Rd, Wythenshawe, M23 9QZ, UK.
出版信息
Br J Clin Pharmacol. 2017 May;83(5):935-937. doi: 10.1111/bcp.13212. Epub 2017 Mar 9.
Abstract
摘要
相似文献
1
Pharmacological treatment for COPD; GOLD 2017 changes direction.慢性阻塞性肺疾病的药物治疗；《慢性阻塞性肺疾病全球倡议（GOLD）2017》改变方向。
Br J Clin Pharmacol. 2017 May;83(5):935-937. doi: 10.1111/bcp.13212. Epub 2017 Mar 9.
2
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?慢性阻塞性肺疾病当前管理概述：我们能否超越 GOLD 建议？
Expert Rev Respir Med. 2018 Jan;12(1):43-54. doi: 10.1080/17476348.2018.1398086. Epub 2017 Nov 3.
3
Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.慢性阻塞性肺疾病的药物治疗：从循证医学到表型分析
Drug Discov Today. 2014 Dec;19(12):1928-35. doi: 10.1016/j.drudis.2014.08.004. Epub 2014 Aug 23.
4
GOLD in 2017: A View From the Spanish COPD Guidelines (GesCOPD).《2017年慢性阻塞性肺疾病全球倡议：西班牙慢性阻塞性肺疾病指南（GesCOPD）视角》
Arch Bronconeumol. 2017 Mar;53(3):89-90. doi: 10.1016/j.arbres.2017.01.001. Epub 2017 Jan 31.
5
[Diagnostic and treatment of chronic obstructive pulmonary disease based on GOLD statement 2011].基于2011年慢性阻塞性肺疾病全球倡议声明的慢性阻塞性肺疾病诊断与治疗
Pol Merkur Lekarski. 2012 Oct;33(196):187-92.
6
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap.哮喘-慢性阻塞性肺疾病重叠综合征的治疗方法
Expert Rev Clin Immunol. 2017 May;13(5):449-455. doi: 10.1080/1744666X.2017.1273109. Epub 2016 Dec 26.
7
Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort.慢性阻塞性肺疾病全球倡议（GOLD）A组和B组慢性阻塞性肺疾病（COPD）患者吸入性糖皮质激素处方的相关因素——台湾阻塞性肺病队列的亚组分析
Int J Chron Obstruct Pulmon Dis. 2015 Sep 14;10:1951-6. doi: 10.2147/COPD.S88114. eCollection 2015.
8
Pharmacological treatment of COPD - New evidence.慢性阻塞性肺疾病的药物治疗——新证据。
Pulmonology. 2019 Mar-Apr;25(2):90-96. doi: 10.1016/j.pulmoe.2018.10.005. Epub 2018 Nov 28.
9
Spirometric Criteria for Chronic Obstructive Pulmonary Disease in Clinical Trials of Pharmacotherapy.药物治疗临床试验中慢性阻塞性肺疾病的肺量计标准
COPD. 2018 Feb;15(1):17-20. doi: 10.1080/15412555.2018.1424815.
10
[Differences between guidelines on management of COPD].[慢性阻塞性肺疾病管理指南之间的差异]
Pneumonol Alergol Pol. 2006;74(2):139-43.
引用本文的文献
1
Efficacy of low molecular weight heparin for chronic obstructive pulmonary disease and respiratory failure: A protocol of systematic review of randomized controlled trials.低分子量肝素治疗慢性阻塞性肺疾病及呼吸衰竭的疗效：一项随机对照试验的系统评价方案
Medicine (Baltimore). 2019 Nov;98(48):e18051. doi: 10.1097/MD.0000000000018051.
2
New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?慢性阻塞性肺疾病的新治疗选择：我们如何确定表型、内型或可治疗特征？
Chronic Obstr Pulm Dis. 2018 Jan 18;5(1):72-80. doi: 10.15326/jcopdf.5.1.2018.0128.
3
What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure?我们可以应用什么来管理伴有急性呼吸衰竭的慢性阻塞性肺疾病急性加重？
Tuberc Respir Dis (Seoul). 2018 Apr;81(2):99-105. doi: 10.4046/trd.2017.0094. Epub 2018 Jan 24.
4
The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.布地奈德福莫特罗超细粉在非“频繁急性加重”慢性阻塞性肺疾病患者中的疗效：FORWARD研究的事后分析
Int J Chron Obstruct Pulmon Dis. 2017 Nov 3;12:3263-3271. doi: 10.2147/COPD.S141416. eCollection 2017.
本文引用的文献
1
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.三联吸入治疗与吸入性皮质类固醇加长效β2-激动剂治疗慢性阻塞性肺疾病（TRILOGY）：一项双盲、平行组、随机对照试验。
Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.
2
Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病药理学治疗的当前争议。
Am J Respir Crit Care Med. 2016 Sep 1;194(5):541-9. doi: 10.1164/rccm.201606-1179PP.
3
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.丙酸倍氯米松/富马酸福莫特罗：在慢性阻塞性肺疾病中的疗效评价。
NPJ Prim Care Respir Med. 2016 Jun 16;26:16030. doi: 10.1038/npjpcrm.2016.30.
4
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.茚达特罗格隆溴铵与沙美特罗氟替卡松治疗 COPD。
N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.
5
A review of national guidelines for management of COPD in Europe.欧洲慢性阻塞性肺疾病管理国家指南综述。
Eur Respir J. 2016 Feb;47(2):625-37. doi: 10.1183/13993003.01170-2015. Epub 2016 Jan 21.
6
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.血液嗜酸性粒细胞与慢性阻塞性肺疾病中吸入性糖皮质激素/长效β-2受体激动剂的疗效
Thorax. 2016 Feb;71(2):118-25. doi: 10.1136/thoraxjnl-2015-207021. Epub 2015 Nov 19.
7
Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.噻托溴铵+奥达特罗在生活质量方面显示出具有临床意义的改善。
Respir Med. 2015 Oct;109(10):1312-9. doi: 10.1016/j.rmed.2015.08.002. Epub 2015 Aug 12.
8
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).阿地溴铵与富马酸福莫特罗固定剂量联合用于慢性阻塞性肺疾病：两项为期六个月的多中心随机研究（ACLIFORM和AUGMENT）中症状与急性加重的汇总分析
Respir Res. 2015 Aug 2;16(1):92. doi: 10.1186/s12931-015-0250-2.
9
Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.血液嗜酸性粒细胞：慢性阻塞性肺疾病中对超细布地奈德/福莫特罗反应的生物标志物
Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5. doi: 10.1164/rccm.201502-0235LE.
10
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.慢性阻塞性肺疾病病死率预测比较 GOLD 2007 及 2011 分期系统：一项个体患者资料的汇总分析。
Lancet Respir Med. 2015 Jun;3(6):443-50. doi: 10.1016/S2213-2600(15)00157-5. Epub 2015 May 17.
Zotero 插件